The therapeutic efficacy and immunomodulatory effects of concurrent IL-33/ST-2 pathway inhibition and albendazole (ABZ) treatment were also evaluated.<h4>Methods</h4>Protein expression levels of IL-33 and ST-2 in liver were examined in a murine model of AE using immunohistochemistry. This evidence concerns the gene IL33 and acrodermatitis enteropathica.